Docs prefer virtual reps to living ones

Assembly-line workers fear being replaced by robots. Now pharma reps can fear losing their places to the Internet. According to a study by Verispan, 47 percent of docs thought they got as much info from e-promotions as face-to-face detailing by reps, and 21 percent thought it was better than the real, live thing.

That's why 10 percent last year opted for electronic detailing instead of in-person rep visits, when they had the choice. "Physicians prefer this form of detailing because they can do the activities on their own...they can learn about the drugs without disrupting patient time with reps in the office," said a Verispan manager.

Another note: Newer docs were most likely to switch to online detailing. Understandable, considering that the younger generation tends to be more comfortable with technology. But that just means that as more and more new docs come on the scene, the proportion of them who prefer interacting with virtual reps rather than real ones is likely to grow.

- read the item at Pharma Marketing Blog
- see the PharmaExec report

Related Articles:
Ranks of sales reps thinning. Sales rep report
Study: Drug ads drown in online noise. Ad report
Docs go cold turkey on industry pay. Report
Dr. Drug Rep tells all. Sales rep report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.